S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

Conditions

• Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - 120 Years

Healthy Volunteers

Not accepted

Interventions

• bevacizumab — BIOLOGICAL
• erlotinib hydrochloride — DRUG

Study Details

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving erlotinib together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with bevacizumab works in treating patients with stage IIIB or stage IV primary non-small cell lung cancer who have never smoked.

Key Dates

Start date

Jul 31, 2007

Status verified

Feb 2020

Primary completion

Aug 31, 2013

Completion

Jan 31, 2014

Study Design

Enrollment

89 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Erlotinib and Bevacizumab

Primary Outcome Measure

Overall Survival [ Time Frame: Disease assessment is performed every 6 weeks for 18 weeks, then every 9-12 weeks until progression up to 2 years. After disease progression, patients must be followed every 3 months for 1 year and then every 6 months for a maximum of 3 years. ]

Locations (153)

Find similar trials in Antioch, CA

Related Studies

• Lung Cancer Biomarkers and Screening
  Recruiting · NYU Langone Health · New York, New York
• DNA Analysis of Blood and Tissue from Patients with Lung Cancer
  Recruiting · Massachusetts General Hospital · Boston, Massachusetts
• Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
  Recruiting · Stanford University · Stanford, California
• Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
  Recruiting · University of California, Davis · Sacramento, California